Jiongyu Ren, Qiang Wen, Shiye Du, Xiaoguang Ge, Lu Li, Lan Wei, Shi Gao
{"title":"Tumor microenvironment-responsive metal-natural polyphenol nanozyme for radiosensitization by interfering glucose metabolism and redox homeostasis","authors":"Jiongyu Ren, Qiang Wen, Shiye Du, Xiaoguang Ge, Lu Li, Lan Wei, Shi Gao","doi":"10.1016/j.jconrel.2025.114219","DOIUrl":null,"url":null,"abstract":"Radiotherapy (RT) still faces great challenges with tumor hypoxia, antioxidant mechanisms and high glucose metabolism. Herein, we report a tumor microenvironment (TME)-responsive ruthenium-natural polyphenol phloretin (RPP) nanozyme with glucose oxidase (GOx), catalase (CAT), peroxidase (POD) and glutathione peroxidase (GPX) -like activities, which serves as an efficient and safe radiosensitizer for enhanced RT. Under an acidic TME, RPP nanozyme aerobically consumes the intracellular glucose and reduces the production of lactic acid, and meanwhile, the <em>in-situ</em> exposure of phloretin can block the uptake of extracellular glucose by inhibiting glucose transporters, making it more efficient to inhibit glycolysis and minimize oxygen consumption. Moreover, RPP nanozyme can not only rapidly catalyze hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) into reactive oxygen species (ROS) and oxygen to alleviate tumor hypoxia, but also down-regulate the intracellular glutathione (GSH) and lactic acid level to overcome antioxidant metabolism. Both <em>in vitro</em> and <em>in vivo</em> studies manifest that RPP nanozyme significantly enhance the radiosensitivity of 4 T1 tumor cells. Besides, <em>in vivo</em> positron emission tomography imaging, utilizing clinical imaging agents, validates the decreased glucose uptake and hypoxia relief treated by RPP nanozyme. The facile RPP nanozyme with the regulating ability of TME can achieve TME-responsive radiosensitization, providing promising potential for tumor therapy.","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"311 1","pages":""},"PeriodicalIF":11.5000,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Controlled Release","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jconrel.2025.114219","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0
Abstract
Radiotherapy (RT) still faces great challenges with tumor hypoxia, antioxidant mechanisms and high glucose metabolism. Herein, we report a tumor microenvironment (TME)-responsive ruthenium-natural polyphenol phloretin (RPP) nanozyme with glucose oxidase (GOx), catalase (CAT), peroxidase (POD) and glutathione peroxidase (GPX) -like activities, which serves as an efficient and safe radiosensitizer for enhanced RT. Under an acidic TME, RPP nanozyme aerobically consumes the intracellular glucose and reduces the production of lactic acid, and meanwhile, the in-situ exposure of phloretin can block the uptake of extracellular glucose by inhibiting glucose transporters, making it more efficient to inhibit glycolysis and minimize oxygen consumption. Moreover, RPP nanozyme can not only rapidly catalyze hydrogen peroxide (H2O2) into reactive oxygen species (ROS) and oxygen to alleviate tumor hypoxia, but also down-regulate the intracellular glutathione (GSH) and lactic acid level to overcome antioxidant metabolism. Both in vitro and in vivo studies manifest that RPP nanozyme significantly enhance the radiosensitivity of 4 T1 tumor cells. Besides, in vivo positron emission tomography imaging, utilizing clinical imaging agents, validates the decreased glucose uptake and hypoxia relief treated by RPP nanozyme. The facile RPP nanozyme with the regulating ability of TME can achieve TME-responsive radiosensitization, providing promising potential for tumor therapy.
期刊介绍:
The Journal of Controlled Release (JCR) proudly serves as the Official Journal of the Controlled Release Society and the Japan Society of Drug Delivery System.
Dedicated to the broad field of delivery science and technology, JCR publishes high-quality research articles covering drug delivery systems and all facets of formulations. This includes the physicochemical and biological properties of drugs, design and characterization of dosage forms, release mechanisms, in vivo testing, and formulation research and development across pharmaceutical, diagnostic, agricultural, environmental, cosmetic, and food industries.
Priority is given to manuscripts that contribute to the fundamental understanding of principles or demonstrate the advantages of novel technologies in terms of safety and efficacy over current clinical standards. JCR strives to be a leading platform for advancements in delivery science and technology.